Skip to main content

Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation

Completed · NCT03729830

Conditions: Paroxysmal Atrial Fibrillation

At a glance

Research payments reported, 2025
$15,090
U.S. investigators named
6
Sites paid
6
Planned or actual enrollment
415

About the trial

Sponsor
Boston Scientific Corporation
Tested
Boston Scientific Open Irrigated Ablation Catheters (device)
Dates
Started 2019-03-04; completion 2024-05-03
Results posted
Yes

To obtain data for the Rhythmia™ Mapping System in conjunction with Boston Scientific Open-Irrigated (OI) Catheters for ablation of Paroxysmal Atrial Fibrillation (PAF) according to current international and local guidelines. Primary objective: To assess acute and long-term outcomes for the Rhythmia Mapping System in conjunction with Boston Scientific Open-Irrigated Ablation Catheters to treat de novo Paroxysmal Atrial Fibrillation. De Novo PAF is defined as subjects undergoing first ablation procedure for PAF with no prior left atrial ablation (RF, Cryo, Surgical).

From ClinicalTrials.gov, last updated 2026-01-21. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $15,090 in research payments for this study in 2025 (8 payments).

Products named: General - Therapies

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.